Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Ibrutinib in Advanced Systemic Mastocytosis

NCT02415608 is registered in ClinicalTrials.gov with Jason Robert Gotlib as lead sponsor.

NCT NCT02415608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02415608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Ibrutinib in Advanced Systemic Mastocytosis
Lead sponsor
Jason Robert Gotlib
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2015
Completion date
June 14, 2017
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive systemic mastocytosis, mast cell leukemia, systemic mastocytosis